Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
Atossa Therapeutics 和 Quantum Leap Healthcare 啓動 I-SPY 2 臨床試驗，以評估 (Z)-恩多昔芬與阿貝馬西利布聯合用於患有 ER+/HER2-乳腺癌的女性
The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer. Participants will receive 40mg (Z)-endoxifen once daily in combination with 150mg abemaciclib twice daily for a total of 24 weeks prior to surgery.
新的研究組將招收大約20名新診斷的雌激素受體陽性（ER+）/人類表皮生長因子受體2陰性（HER2-）浸潤性乳腺癌的女性。參與者將在手術前接受每天一次40mg（Z）-內昔芬與150mg abemaciclib聯合使用，每天兩次，共持續24周。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。